(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €38.70 | 2.85% | 8.13% |
| MERCK AND CO INC (MRK.PA) | €101.40 | 2.61% | 29.69% |
| CEGEDIM (CGM.PA) | €19.84 | 2.48% | 4.5% |
| ESSILORLUXOTTICA (EL.PA) | €170.30 | 1.75% | 6.16% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
2.85% Forward Dividend Yield and 8.13% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.85.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.58. Meaning, the purchaser of the share is investing €13.58 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
More news about BOIRON.
2. MERCK AND CO INC (MRK.PA)
2.61% Forward Dividend Yield and 29.69% Return On Equity
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €4.82.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 21.04. Meaning, the purchaser of the share is investing €21.04 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.69%.
Volume
Today’s last reported volume for MERCK AND CO INC is 250 which is 69.43% below its average volume of 818.
Moving Average
MERCK AND CO INC’s worth is below its 50-day moving average of €103.30 and above its 200-day moving average of €99.53.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2023, the estimated forward annual dividend rate is 2.7 and the estimated forward annual dividend yield is 2.61%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MERCK AND CO INC’s EBITDA is 4.88.
More news about MERCK AND CO INC.
3. CEGEDIM (CGM.PA)
2.48% Forward Dividend Yield and 4.5% Return On Equity
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals in France, other European countries, and internationally. It operates in two segments, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This segment also provides solutions for hosting, HR and payroll management outsourcing, electronic data exchange, and data processing services. The Healthcare Professionals division sells management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 19.84. Meaning, the purchaser of the share is investing €19.84 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.5%.
Moving Average
CEGEDIM’s value is above its 50-day moving average of €19.05 and way above its 200-day moving average of €17.22.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CEGEDIM’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 555.21M for the twelve trailing months.
Yearly Top and Bottom Value
CEGEDIM’s stock is valued at €19.84 at 17:30 EST, way under its 52-week high of €25.00 and way higher than its 52-week low of €13.56.
More news about CEGEDIM.
4. ESSILORLUXOTTICA (EL.PA)
1.75% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.87.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 34.97. Meaning, the purchaser of the share is investing €34.97 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 24.49B for the twelve trailing months.
Volatility
ESSILORLUXOTTICA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.06%, a negative 0.54%, and a positive 1.09%.
ESSILORLUXOTTICA’s highest amplitude of average volatility was 0.94% (last week), 1.08% (last month), and 1.09% (last quarter).
More news about ESSILORLUXOTTICA.
